Evaluation of the efficacy of hyperbaric oxygen therapy in the management of chronic nonhealing ulcer and role of periwound transcutaneous oximetry as a predictor of wound healing response: A randomized prospective controlled trial.

What Researchers Did

Researchers conducted a randomized controlled trial with 30 patients to evaluate hyperbaric oxygen therapy (HBOT) for chronic nonhealing ulcers and the predictive role of transcutaneous oximetry (TCOM).

What They Found

Patients receiving HBOT showed a 59% reduction in wound area, compared to a 26% increase in the conventional treatment group. Complete healing occurred in 3 HBOT patients versus none in the control group, and HBOT also reduced the need for surgical debridement (6 vs 10 patients) and amputation (1 vs 5 patients).

What This Means for Canadian Patients

For Canadian patients with chronic nonhealing ulcers, hyperbaric oxygen therapy could be a valuable adjunctive treatment to improve wound healing. This therapy may help reduce the need for surgical interventions like debridement and amputation, leading to better patient outcomes.

Canadian Relevance

This study was not conducted in Canada and does not have a direct Canadian connection.

Study Limitations

A limitation of this study is its relatively small sample size of 30 patients, which may limit the generalizability of the findings.